From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – GU
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in GU
Dr Jérémy Blanc, a medical oncologist in training from the Institut Jules Bordet in Brussels, shares the latest information regarding biomarkers in RCC from the oral abstract session at ASCO
Prof Dr Piet Dirix, a radiation oncologist at the Iridium Network in Antwerp, highlights the most interesting presentations from the oral abstract session on prostate, testicular, and penile cancer.
Dr Jérémy Blanc, medical oncologist in training from the Institut Jules Bordet, Brussels selected highlights on bladder cancer from ASCO24. Dr Jae-Lyun Lee presented the first results from the Ultma
Prof Piet Dirix, radiation oncologist at the Iridium Network in Antwerp highlights the most interesting presentations from the oral abstract session on prostate cancer (PCa). Extensive preclinical data suggest that
In-depth stories about GU
Prof Emmanuel Seront, a medical oncologist at Clinique Universitaires Saint-Luc in Brussels, shares his insights on a post hoc analysis of the CheckMate 901 trial.
The CheckMate 901 trial is
Dr Shilpa Gupta, a medical oncologist at the Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, presented patient-reported outcomes (PRO) from the EV-302/KEYNOTE-A39 trial.
Dr Michiel Van Der Heijden, a medical oncologist at the Netherlands Cancer Institute, Amsterdam, Netherlands, presented subgroup analyses from the EV-302/KEYNOTE-A39 trial.
At the rapid oral abstract session at the ASCO meeting, Dr Jérémy Blanc, a medical oncologist in training from the Institut Jules Bordet, Brussels, presented the survival data from the
GU poster selection
In a subgroup population analysis from the DESTINY-Pan Tumor 02 study, the efficacy of T-DXd in patients with urothelial cancer expressing the HER2 receptor was evaluated. The study enrolled patients